Velpatasvir

Velpatasvir
Clinical data
Trade names	Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)
Routes of; administration	Oral (tablets)
ATC code	J05AP55 (WHO) (combination with sofosbuvir); J05AP56 (WHO) (combination with sofosbuvir and voxilaprevir);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99.5%
Metabolism	Liver (CYP2B6, 2C8, 3A4)
Elimination half-life	15 hours
Excretion	Feces (94%), urine (0.4%)
Identifiers
	IUPAC name Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate;
CAS Number	1377049-84-7;
PubChem CID	67683363;
DrugBank	DB11613;
ChemSpider	34501056;
UNII	KCU0C7RS7Z;
KEGG	D10806;
ChEBI	CHEBI:133009 ;
CompTox Dashboard (EPA)	DTXSID70722565 ;
Chemical and physical data
Formula	C49H54N8O8
Molar mass	883.019 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1;
	InChI InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1; Key:FHCUMDQMBHQXKK-CDIODLITSA-N;

Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

Clinical data

Trade names	Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)
Routes of administration	Oral (tablets)
ATC code	J05AP55 (WHO) (combination with sofosbuvir) J05AP56 (WHO) (combination with sofosbuvir and voxilaprevir)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	>99.5%
Metabolism	Liver (CYP2B6, 2C8, 3A4)
Elimination half-life	15 hours
Excretion	Feces (94%), urine (0.4%)
Identifiers
IUPAC name Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
CAS Number	1377049-84-7
PubChem CID	67683363
DrugBank	DB11613
ChemSpider	34501056
UNII	KCU0C7RS7Z
KEGG	D10806
ChEBI	CHEBI:133009^Y
CompTox Dashboard (EPA)	DTXSID70722565
Chemical and physical data
Formula	C₄₉H₅₄N₈O₈
Molar mass	883.019 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
InChI InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 Key:FHCUMDQMBHQXKK-CDIODLITSA-N